July 2022
Investor Update
At the halfway mark of 2022, the team at EpiVario is filled with excitement, for our recent accomplishments and upcoming milestones.

In the first half of the year, we applied for a number of grant funding opportunities and participated in various investor pitch events including, most recently, Startup Stadium at the BIO International Convention. **We are in the process of finalizing a phase 1 grant with one of the NIH agencies.** This will propel EpiVario towards space at a biotech incubator and our first employee hires. Also, within the next month we expect to publish a **new article in the journal PNAS.**

Additionally, we plan to raise capital: first, through extending our seed offering, and second, through a series A equity raise in Q4 2022. This will help us accelerate the development of our first drug for smoking cessation.
Previously Reported Milestones

• **Added expert consultants**
  - Dr. Paul Kenny, Mount Sinai
  - Dr. Caryn Lerman, University Southern California
  - Dr. Howard Becker, Medical University of South Carolina

• **New preclinical collaborations**
  - Stress-depression study with Dr. Matt Lattal, OHSU
  - Alcohol addiction study with Dr. Becker
  - Nicotine addiction study with Dr. Kenny
  - Opioid addiction study with NIDA intramural research program
  - Alcohol addiction pilot study in monkey model with Dr. Paul Czoty, Wake Forest

• **Other studies**
  - Behavioral time-course study
  - Medicinal chemistry
Recent Milestones

• **Grant Funding**
  - Applied for Dept of Defense grant to develop a therapy for PTSD
  - Received notice of intent to fund by Natl Institute of Alcohol Abuse and Alcoholism

• **Pitch Competition**
  - Startup Stadium pitch contest at BIO International Conference
    - https://www.bio.org/events/bio-international-convention/announcements/start-stadium
  - Finalist in Falling Walls Venture competition

• **Publication**
  - Article accepted for publication in Proceedings of the National Academy of Sciences (PNAS)
    - https://www.bio.org/events/bio-international-convention/announcements/start-stadium
Recent Milestones

• **Lead optimization**
  • Designed and tested about 20 novel compounds
  • Identified lead compound after rodent studies
  • Filed new patent application on the compounds

• **Other studies**
  • Monkey alcohol study with Dr. Paul Czoty at Wake Forest – in progress
  • Opioid addiction rodent study at NIDA – in progress
Focus on Addiction Therapy

A Large Market Starving for Pharmacotherapies
**Collaborator: Dr. Howard Becker, MUSC**

- Test novel compounds in rodent alcohol addiction model
- Goal: develop new drug to treat alcohol use disorder
Development of a Smoking Cessation Drug

Preclinical Collaborator: Dr. Paul Kenny, Mount Sinai

- Director, Drug Discovery Institute at Mount Sinai
- Ward-Coleman Professor and Chair of the Nash Family Department of Neuroscience
- Cofounder, Eolas Therapeutics

• Proof-of-Concept in Translative nicotine addiction model

Clinical Collaborator: Dr. Caryn Lerman, USC

- Director of USC Norris and the H. Leslie and Elaine S. Hoffman Professor in Cancer Research

https://uscnorriscancer.usc.edu/lerman/  
https://icahn.mssm.edu/profiles/paul-j-kenny
Development of a Smoking Cessation Drug

**Translating Preclinical PoC**
- Treated rats dramatically improved vs control
- Significant reduction of nicotine craving
  - Upon ceasing nicotine
  - Upon cue-induced reinstatement

**Clinical Strategy and Development**
- Lead by Dr. Caryn Lerman, USC
- Treatment of patients actively seeking to quit
- Treatment occurs while smoking

EPV-001

- Reduce craving
  - Maintain abstinence
  - Prevent relapse
What’s Next
Future milestones

• Advancing lead candidate drug for addiction therapies, starting with smoking cessation

• Grant funding
  • Funding from NIAAA this fall for alcohol use disorder
  • File grant application with Dr. Paul Kenny with BPN Program

• Opioid addiction study at NIDA Intramural Research Program

• Alcohol addiction study on monkeys with Dr. Paul Czoty, Wake Forest

• Additional Seed financing this summer

• Series A fundraise targeting $15MM in Q4 2022